Trials / Completed
CompletedNCT03068312
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivacaftor | IVA 150 mg tablet. |
| DRUG | Placebo | Placebo matched to IVA tablet. |
Timeline
- Start date
- 2017-07-18
- Primary completion
- 2018-12-18
- Completion
- 2018-12-18
- First posted
- 2017-03-01
- Last updated
- 2020-02-26
- Results posted
- 2020-01-06
Locations
1 site across 1 country: Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03068312. Inclusion in this directory is not an endorsement.